Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Orexigen Therapeutics Inc (NASDAQ:OREX)

1.64
Delayed Data
As of Feb 12
 -0.01 / -0.61%
Today’s Change
1.39
Today|||52-Week Range
9.37
-4.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$238.5M

Company Description

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of pharmaceutical product candidates for the treatment of obesity. Its product candidate, NB32, is an investigational medicine for weight loss and the maintenance of weight loss; and Empatic used for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

Contact Information

Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
La Jolla California 92037
P:(858) 875-8600
Investor Relations:
(858) 875-8629

Employees

Shareholders

Other institutional30.75%
Mutual fund holders29.86%
Individual stakeholders16.70%

Top Executives

Michael A. NarachiPresident, CEO, CFO & Director
Thomas R. CannellChief Commercial Officer & Executive VP
Thomas P. LynchSecretary, Executive VP & General Counsel
Preston S. KlassenExecutive Vice President-Global Development
Stephen A. MogliaPrincipal Accounting Office